Technetium [99mTc] H7ND
Alternative Names: PMD-12; Technetium [99mTc]-H7NDLatest Information Update: 04 Jul 2024
At a glance
- Originator Jiaxing Pharmadax Genesis Pharmaceutical Technology; Unknown
- Developer Jiaxing Pharmadax Genesis Pharmaceutical Technology
- Class Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Jun 2024 Preclinical trials in Solid tumours (Diagnosis) in China (IV), prior to June 2024
- 05 Jun 2024 Jiaxing Pharmadax Genesis Pharmaceutical Technology plans a phase I trial for Solid tumours (Diagnosis) (IV), in May 2024(NCT06443710)
- 14 May 2024 Phase-I clinical trials in Solid tumours (Diagnosis) in China (IV) (NCT06443710)